211 related articles for article (PubMed ID: 36409491)
21. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
[TBL] [Abstract][Full Text] [Related]
23. Stroke Outcomes in the COMPASS Trial.
Sharma M; Hart RG; Connolly SJ; Bosch J; Shestakovska O; Ng KKH; Catanese L; Keltai K; Aboyans V; Alings M; Ha JW; Varigos J; Tonkin A; O'Donnell M; Bhatt DL; Fox K; Maggioni A; Berkowitz SD; Bruns NC; Yusuf S; Eikelboom JW
Circulation; 2019 Feb; 139(9):1134-1145. PubMed ID: 30667279
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
[TBL] [Abstract][Full Text] [Related]
25. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
26. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
Vogel B; Baber U; Cohen DJ; Sartori S; Sharma SK; Angiolillo DJ; Farhan S; Goel R; Zhang Z; Briguori C; Collier T; Dangas G; Dudek D; Escaned J; Gil R; Han YL; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta SR; Moliterno D; Ohman EM; Sardella G; Witzenbichler B; Gibson CM; Pocock S; Huber K; Mehran R
JAMA Cardiol; 2021 Sep; 6(9):1032-1041. PubMed ID: 33991416
[TBL] [Abstract][Full Text] [Related]
27. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR; Félix C; Guzik TJ; Hart RG; Maggioni AP; Muehlhofer E; Sharma M; Shestakovska O; Yusuf S
J Am Coll Cardiol; 2021 Jul; 78(1):14-23. PubMed ID: 34210409
[TBL] [Abstract][Full Text] [Related]
28. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
Branch KRH; Probstfield JL; Bosch J; Bhatt DL; Maggioni AP; Muehlhofer E; Avezum A; Widimsky P; Connolly SJ; Yi Q; Shestakovska O; Yusuf S; Eikelboom JW
Am Heart J; 2023 Apr; 258():60-68. PubMed ID: 36646196
[TBL] [Abstract][Full Text] [Related]
29. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S;
Am J Cardiovasc Drugs; 2024 Jan; 24(1):117-127. PubMed ID: 38153624
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
32. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
Bhagirath VC; Eikelboom JW; Anand SS
Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
[TBL] [Abstract][Full Text] [Related]
33. Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomized Trial.
Leong DP; Bosch J; Bhatt DL; Avezum A; Yuan F; Yusuf S; Eikelboom JW
Can J Cardiol; 2024 Jun; ():. PubMed ID: 38914270
[TBL] [Abstract][Full Text] [Related]
34. Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Merkler AE; Pearce LA; Kasner SE; Shoamanesh A; Birnbaum LA; Kamel H; Sheth KN; Sharma R
JAMA Neurol; 2021 Dec; 78(12):1454-1460. PubMed ID: 34694346
[TBL] [Abstract][Full Text] [Related]
35. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Easton JD; Denison H; Evans SR; Knutsson M; Amarenco P; Albers GW; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC;
Int J Stroke; 2019 Dec; 14(9):908-914. PubMed ID: 31092152
[TBL] [Abstract][Full Text] [Related]
36. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S
Eur Heart J Qual Care Clin Outcomes; 2023 Aug; 9(5):502-510. PubMed ID: 36001989
[TBL] [Abstract][Full Text] [Related]
38. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
39. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI).
Bainey KR; Welsh RC; Connolly SJ; Marsden T; Bosch J; Fox KAA; Steg PG; Vinereanu D; Connolly DL; Berkowitz SD; Foody JM; Probstfield JL; Branch KR; Lewis BS; Diaz R; Muehlhofer E; Widimsky P; Yusuf S; Eikelboom JW; Bhatt DL;
Circulation; 2020 Apr; 141(14):1141-1151. PubMed ID: 32178526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
